Thurleigh, United Kingdom
Thurleigh, United Kingdom

Time filter

Source Type

Patent
Mologic Ltd | Date: 2015-03-02

Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.


Patent
Mologic Ltd | Date: 2015-03-04

Methods are provided for determining the presence of an analyte present in a liquid sample involving: contacting the liquid sample with a predetermined amount of an analogue of the analyte and an excess of a first binding moiety, wherein the first binding moiety is capable of binding each of the analyte and the analogue independently; contacting the mixture with a second binding moiety; and determining the level of a signal indicative of the presence of the analogue-first binding moiety complex bound to the second binding moiety, wherein if the level of the signal determined is lower than the level of a maximum signal determined when no analyte is present, then analyte is present in the sample. Corresponding kits are also provided.


Patent
Mologic Ltd | Date: 2017-01-04

Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.


Patent
Mologic Ltd | Date: 2017-01-11

Methods are provided for determining the presence of an analyte present in a liquid sample involving: contacting the liquid sample with a predetermined amount of an analogue of the analyte and an excess of a first binding moiety, wherein the first binding moiety is capable of binding each of the analyte and the analogue independently; contacting the mixture with a second binding moiety; and determining the level of a signal indicative of the presence of the analogue-first binding moiety complex bound to the second binding moiety, wherein if the level of the signal determined is lower than the level of a maximum signal determined when no analyte is present, then analyte is present in the sample. Corresponding kits are also provided.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 150.00K | Year: 2016

Our target is to develop a simple, easy to use, diagnostic system for use in the home by COPD patients to gain early warning of acute exacerbation (AECOPD) and stratify them to the most suitable and effective therapy. This will determine the use of antibiotic, anti-inflammatory or bronchodilator medication (combinations of some of these might be required). COPD is a troublesome worldwide disease with no cure, causing substantial debilitation through breathlessness that gets worse each time there is an exacerbation. Typically, the course of the disease follows periods of stability interspersed with damaging AECOPD episodes from which patients usually do not make a full recovery. Medication is needed when an exacerbation starts, rather than during the stable disease state. COPD is a large and growing world-wide problem. It is a progressively heavy burden for individual patients, carers and health services. But, despite its prevalence and impact, it is not managed well. Delays in diagnosis cause patients to miss out on prompt appropriate medication, while the lack of diagnostically guided AECOPD treatment exposes some patients to inappropriate antibiotic and/or corticosteroid therapy. Inappropriate antibiotic use should be avoided in order to minimise development of antibiotic resistance, as well as damaging side effects. There are substantial side effects of corticosteroids which also should be avoided. In July 2015, the NIHR Horizon Scanning Research & Intelligence Centre published a report on new and emerging technologies for the diagnosis and monitoring of COPD, which specifically highlighted the need for better ways to identify the cause of AECOPD, in order to guide steroid versus antibiotic treatment. The report recommended that promising technologies should be the focus of translational and clinical research funding. Moreover, the NICE Database of Uncertainties about the Effects of Treatments (DUET) highlights the use of corticosteroids and antibiotics for AECOPD as important treatment uncertainties. There is therefore a clear need for a rapid, easy and early stratification test to both identify AECOPD and to stratify sufferers into groups for treatment with antibiotics or steroids. The outcome from this project will be the development of a multiplexed, urinary biomarker diagnostic test system with integrated, personalised biomarker level interpretation algorithm for monitoring the inflammatory status of patients suffering from chronic inflammatory disease at home, with a practical simplicity and diagnostic accuracy never previously possible. This project is bold and ambitious. If successful it will have a significant positive impact on patients’ quality of life, as well as reducing health care costs, whilst representing a major business opportunity for Mologic and the UK medical diagnostics sector.


Grant
Agency: GTR | Branch: EPSRC | Program: | Phase: Research Grant | Award Amount: 11.06M | Year: 2013

The emergence and re-emergence of infectious diseases is one of the greatest threats to human health. By their very nature, outbreaks of infectious disease can spread rapidly, causing enormous losses to health and livelihood. For example, an estimated 35-million people are HIV-infected, antibiotic resistant pathogens such as MRSA are a major global public health problem and pandemic influenza is rated as the greatest national risk on the UK government risk register (Cabinet Office National Risk Register for Civil Emergencies 2012 Edition). Early diagnosis plays a vital role in the treatment, care and prevention of infectious diseases. However worldwide, many infections remain undiagnosed and untreated or are diagnosed at the late stage due to poor diagnostic tools, resulting in on-going transmission of serious infections or delay in the identification of emerging threats, leading to major human and economic consequences for millions of people. Our vision is to establish an EPSRC Interdisciplinary Research Centre to create a new generation of early-warning sensing systems to diagnose, monitor & prevent the spread of infectious diseases. This large scale collaboration will bring together scientists, engineers and computer scientists from University College London, Imperial College, London School of Hygiene and Tropical Medicine and the University of Newcastle together with NHS stakeholders, the Health Protection Agency and industry partners. Working across and beyond traditional research boundaries, the IRC will pioneer innovative nano-enabled mobile diagnostic tests which can be used in GP surgeries, community settings and developing countries, linked to smart digital-surveillance systems which search for information on the web to detect early indicators of diseases. The tremendous expansion in mobile phone technology with an estimated 6 billion users worldwide, provides new opportunities for point-of-care diagnostics with inbuilt capacity to securely transmit results to public healthcare systems. The challenge is to create robust multimarker sensor platforms that can diagnose early infections with high sensitivity and specificity. Our strategy will seamlessly integrate the scientific excellence underpinning recent breakthroughs by our team in diverse areas of biomarker discovery, capture coatings, nanoparticles, nanopatterning, sensor systems, wireless connectivity, data mining and health economic analysis of diagnostics. Moreover we will explore innovative new strategies to search for early indicators of infection (herein we coin the phrase e-markers) by searching through millions of web-accessible information sources including Google, Facebook and Twitter to identify outbreaks even from people who do not attend clinics or from geographical regions that are invisible to traditional public health efforts. By providing doctors, community workers and public health organisations with real-time, geographically-linked information about emerging infections which will be visualised on a dashboard display, we will support more rapid, stratified, integrated evidence-based interventions, benefitting individuals and populations. Our disruptive early warning sensing capabilities will bring major human and economic benefits to the NHS and global healthcare systems. The ultimate beneficiaries will be patients since early diagnosis will empower them to gain faster access to better treatments, helping to reduce suffering and risk of death. Society will benefit by preventing the onwards spread of infection by people who are unaware of their infection and preserve the effectiveness of precious antimicrobial medicines for future generations. The NHS and healthcare systems will benefit by simplifying patient pathways allowing tests and results to be given in a single visit and so provide a more cost-effective solution of community based care. Our technologies will also provide new commercial opportunities for British industry.


Patent
Mologic Ltd | Date: 2016-01-04

An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 522.80K | Year: 2016

Virus-like particles (VLPs) are a flexible delivery platform that provides potential for presenting multiple antigens to the immune system concurrently. Hepatitis B core antigen self assembles to form highly stable, immunogenic VLPs in a relatively low cost yeast expression system. The viral protein can be adapted to display foreign antigens on spikes that protrude from the surface of the VLPs. This technology circumvents the need for high cost, high containment production facilities, cold transportation and storage. Our goal is to produce a cost effective, second generation Q fever vaccine, using VLP technology as a production platform. In initial proof of concept studies, the Mologic-Dstl-Iceni Diagnostics consortium has successfully produced and tested Burkholderia pseudomallei vaccine candidates based on yeast-produced VLPs presenting either peptide or polysaccharide antigens. These candidates were efficacious in a mouse model of Melioidosis, demonstrating the readiness of this technology for roll out for antibacterial vaccine production. In the current proposal, we will consolidate and extend our work on this platform, applying it to Coxiella burnetii, the causative agent of Q Fever, which is listed as an agent of concern by the WHO and UN. Q fever is found worldwide and there is high prevalence in low income countries. This VLP platform bid will draw on expertise in Coxiella burnetii antigenicity to develop a vaccine against Q fever. It has been shown that C. burnetii lipopolysaccharide (LPS) provides protection against challenge, indicating that it is a key protective antigen. LPS itself is a T-cell independent antigen; conjugation to a protein carrier can improve antibody isotype development and crucially stimulate B cell memory. Therefore, to increase vaccine efficacy and develop immune memory to Coxiella, we propose conjugating native C. burnetii LPS, or synthetic fragments thereof, to VLP carriers. In parallel, we will express previously identified C. burnetii protein surface antigens on VLPs, providing material for potential blending with LPS-VLP conjugates to produce multi-antigen vaccines. The novel VLP vaccines produced in this study will be tested in our established mouse model of C. burnetii aerosol infection; immune responses will be determined and related to the vaccine efficacy. Several VLP vaccines have already been licensed for human use, demonstrating an established path to market. The opportunity to manufacture without high level containment will result in inexpensive vaccines where manufacture can be transferred to low income settings. This will serve to pave the way for future development of low-cost vaccines for other globally significant pathogens.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 878.63K | Year: 2017

Sepsis is one of the most common deadly diseases and one of the leading causes of death in the developed world exerting a huge human and economic toll. In the UK there are over 100,000 cases and 37,000 deaths annually. Rapid diagnosis is critical to the effective treatment of the patient and offers the prospect of reduced mortality but existing diagnostic tools lack the sensitivity and/or specificity needed for effective stratification of sepsis to enable early, effective treatment. Mologic is developing an easy-to-use, 10 minute lateral flow based assay that can be used in hospital A&E, wards and intensive care units by bedside nurses to provide rapid discrimination of sepsis. This will enable faster treatment, stratification of patients by degree of risk into appropriate care areas, and financial savings in hospital systems by both reducing complications and overtreatment. The single use cartridges will be compatible with a sample of whole blood which could be obtained from a fingerprick or a venous blood sample.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.55M | Year: 2015

MASSTRPLAN will train the next generation of interdisciplinary research leaders in advanced molecular analytical techniques to detect oxidized phospholipids & proteins in biological & clinical samples, evaluate their biochemical roles in inflammation, and translate these findings to develop new diagnostic tools. Chronic inflammatory diseases such as diabetes, cardiovascular disease (CVD) & cancer are major causes of mortality and cost the EU economy dearly in healthcare and lost working time; CVD alone is estimated to be responsible for 47% of deaths and to cost the EU 196 billion a year. Scientists able to develop advanced analytical tools for detecting oxidative biomolecule modifications and assessing their contribution to cell dysfunction & disease are urgently needed. The objectives of MASSTRPLAN are to 1) train early stage researchers (ESRs) in advanced and novel chromatography, mass spectrometry, and complementary techniques including microscopy and bioinformatics to detect challenging heterogeneous biomolecule modifications and determine their functional effects; 2) give ESRs a broad perspective on relevance & mechanisms of oxidative modifications in pathophysiology and biotechnology; 3) enable ESRs trained in technology development to engage effectively with the clinical sector; and 4) train ESRs in translational and development skills to produce new protocols, materials and commercializable diagnostic tools. The ETN will achieve this by bringing together 10 beneficiaries and 15 partners from academic, industrial and healthcare organizations working in analytical, bioinformatic, biological, clinical & biotech fields to provide multidisciplinary, cross-sector training. Extensive mobility, industrial secondments and network-wide training will yield a cohort of analytical scientists with the unique theoretical, technological, and entrepreneurial skill set to yield new understanding of oxidative inflammatory disorders, leading to better tools and therapies.

Loading Mologic Ltd collaborators
Loading Mologic Ltd collaborators